Keros doses first patient in Phase 3 RENEW trial of elritercept; $10M milestone from Takeda

Keros Therapeutics, Inc.

First patient dosed in Phase 3 RENEW trial of elritercept for adults with transfusion-dependent anemia with very low, low, or intermediate risk MDS.
Milestone payment of $10 million triggered from Takeda under global license agreement.
Keros received $200M upfront in Feb 2025; eligible for milestones exceeding $1.1B and tiered royalties.
RENEW is global, randomized, double-blind, placebo-controlled; primary endpoint is reduction in red blood cell transfusions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.